Li-Fraumeni syndrome
Li-Fraumeni syndrome
Week 1
Week 1
Nuclear structure
DNA structure
Translation of mRNA
Amino acids and protein folding
Transcription of DNA
DNA mutations
Acute radiation syndrome
McCune-Albright syndrome
Fanconi anemia
Lesch-Nyhan syndrome
Orotic aciduria
Cell cycle
Gene regulation
Epigenetics
Protein structure and synthesis
DNA replication
Nucleotide metabolism
Purine and pyrimidine synthesis and metabolism disorders: Pathology review
Bloom syndrome
Myocardial infarction
Lac operon
Drug administration and dosing regimens
Enzyme function
Pharmacokinetics: Drug metabolism
Pharmacokinetics: Drug elimination and clearance
Pharmacokinetics: Drug absorption and distribution
Pharmacodynamics: Drug-receptor interactions
Pharmacodynamics: Desensitization and tolerance
Pharmacodynamics: Agonist, partial agonist and antagonist
DNA damage and repair
Mitosis and meiosis
Adenosine deaminase deficiency
Xeroderma pigmentosum
Li-Fraumeni syndrome
Introduction to pharmacology
Enzyme function
Pharmacodynamics: Drug-receptor interactions
Pharmacodynamics: Agonist, partial agonist and antagonist
Pharmacodynamics: Desensitization and tolerance
Pharmacokinetics: Drug absorption and distribution
Pharmacokinetics: Drug metabolism
Pharmacokinetics: Drug elimination and clearance
Drug administration and dosing regimens
Flashcards
Li-Fraumeni syndrome
0 of 8 complete
Key Takeaways
Li-Fraumeni syndrome (LFS) is a rare inherited genetic disorder. People with Li-Fraumeni syndrome have an increased risk of developing multiple malignancies, typically sarcoma, breast carcinoma, leukemia, and adrenocortical carcinoma cancer.
In this condition, cancers often develop cancer at a young age and people are also more likely to have multiple tumors than people without this syndrome. The cause of Li-Fraumeni syndrome is a mutation in the p53 tumor suppressor gene. This gene provides instructions for making a protein that regulates the cell cycle and prevents genomic mutations that might lead to these cancers.